SAN DIEGO – A decade has transpired since the FDA released its seminal report Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products in March 2004. The FDA did not pull any punches at that time in identifying the industry's inability to improve on the run rate of new product development despite having at its disposal advanced discovery tools such as genomics and investing billions of dollars into research and development. Read More
SAN DIEGO – The Russian government is making a push to diversify its economy away from oil and gas into technology-based industries, including biomedical research. Read More
